We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPIX.L Regulatory News (PPIX)

  • There is currently no data for PPIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ProPhotonix Announces Interim Results

9 Sep 2015 07:00

RNS Number : 4671Y
ProPhotonix Limited
09 September 2015
 

 

September 9, 2015

 

ProPhotonix Limited

 ("ProPhotonix" or "the Company")

 

INTERIM RESULTS FOR THE HALF YEAR ENDED JUNE 30, 2015

 

ProPhotonix Limited (London Stock Exchange - AIM: PPIX , OTC: STKR), a high technology designer and manufacturer of LED illumination systems and laser diode modules, today announces its unaudited interim results for the six months ended June 30, 2015.

 

Financial Highlights

· Revenue decreased 19% to $6.7 million, 10% of which was due to foreign currency rate fluctuation

· Gross profit decreased 13.8% to $2.8 million

· Gross profit margin increased to 41.2% (2014: 38.5%)

· Operating income of $0.1 million (2014: $(0.1) million)

· EBITDA of $0.3 million (2014: $0.1 million)

· Order bookings of $7.7 million

· 1.15 Book-to-Bill ratio (2014: 1.03)

· Percentage revenue by market sectors: 81% industrial, 15% medical, and 4% security & defense

· Percentage revenue by geography: 48% Europe, 39% North America and 13% Rest of World

· Available credit lines of $1.8 million

 

 

Operating Highlights

· Introduced 8 new products in the first half

· Patent application filing for unique thermal management invention

· Awarded two year supply agreement with pharmaceutical customer

· Entered into technology license agreement with technology institute

 

 

Tim Losik, President & CEO, commented:

 

Financial

ProPhotonix Limited's results were impacted by continuing foreign currency exchange rate changes which skew various performance indicators. It is important to assess results in constant dollars, as we did in our 2014 results by highlighting the impact of foreign currency fluctuations last year.

 

Our constant dollar sales in the first half of 2015 were $7.5 million, as compared to the reported revenue of $6.7 million. Currency fluctuations accounted for approximately 10% of our year-on-year revenue decline. Other factors which influenced the fall in revenues included: one significant distributed product customer (which provided $500,000 of revenue at a lower margin in 2014) did not repeat in 2015; declines in two customers' demand rates which we anticipated at the beginning of the year; and expected sales from new customer engineering products which have been delayed. We fully expect these delayed projects to generate meaningful revenue in future periods.

 

Operating profit and EBITDA are much less impacted by currency fluctuations. Many of our expenses are denominated in the same currencies as revenue, a natural hedge, thus mitigating currency translation impact. In addition, the cost reduction implemented by the Company over the last two years significantly reduced our expense structure and break-even point. The Company generated constant dollar operating profit of $0.2 million (a $0.3 million increase on H1 2014) and EBITDA of $0.4 million (an increase of 229% on H1 2014). These results mark the fourth consecutive half-yearly positive EBITDA and second consecutive half-yearly positive operating income, cementing the Company's continued progress.

 

Our first half 2015 orders, in constant dollars, were $8.7 million (a 2% increase on H1 2014), while our backlog at the end of the first half is $6.2 million (an increase of 11% over year-end 2014). In addition, since the end of the first half, the Company has seen strong order bookings of $2.5M for the first two months of the third quarter. Recent announcements of supply agreements are not included in the June 30 or the third quarter-to-date order book, unless firm orders were received from the customers in the relevant periods.

 

The balance sheet continues to strengthen. Term debt of $277,000 was repaid in accordance with the various term loan facilities. Total net available credit from the Company's loan facilities was $1.8 million as of June 30, 2015. The Directors are comfortable with the cash flow of the business considering its plans and available credit facilities.

 

 

Strategy

 

As of June 2015, we mark the two year anniversary of the recapitalization of the Company and the march toward a sustainable business model. Since June 2013, we have focused our efforts on eliminating costs in the business as we strive to win new customers and improve margins.

 

Strategically, the Company is in transition. Historically, our product development has been customer directed. This approach has served us well for specific applications and we continue to offer bespoke product solutions. Over the past two years, we have assessed various markets and product features in order to develop a product strategy focusing on specific markets to complement our direct customer engagement. To this end, we are concentrating our engineering talents in a couple of defined market areas that we believe are poised for fast market expansion.

 

The first of these is the ultra violet (UV) LED and laser market for various applications including: printing, curing, 3D printing, bio-luminescence, medical microscopy, and other applications. Today, we also announced our latest UV LED light within the Cobra CureTM family, which will be the first of several new products in this line up. As stated in the Cobra Cure announcement, the UV LED market is projected to grow at an annual rate of 40% between 2014 and 2019. For more information on Cobra Cure, please visit our website at www.prophotonix.com/products/UV-Solutions/.

 

Our other focus is on the continuing market requirement for multi-wavelength devices and systems; both laser and LED solutions. More and more customers are calling for multi-wavelength solutions requiring innovative optics, complex electronics, sensing capabilities, and software control. We see obvious opportunities which include a broad range of optical sensing and inspection applications in microscopy, industrial and security markets. We are in the research and development phase of these products and expect to announce various laser and LED products in the coming months.

 

Enquiries:

 

 

ProPhotonix Limited

Tim Losik, President & CEO

Tel: +1 603 893 8778

ir@prophotonix.com

 

N+1 Singer

Ben Wright, Richard Salmond

Tel: +44 (0) 207 496 3000

Nominated Adviser and Broker

 

 

About ProPhotonix

 

ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology independent designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Oclaro), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.

 

Half Year 2015 Financial Results

 

Revenue for the half year ended June 30 2015 was $6.7 million, a decrease of 19% compared with $8.3 million in the same period of 2014. Gross profit was $2.8 million, a decrease of 14% compared to $3.2 million in the first half of 2014. Gross profit margin improved to 41.2% from 38.5% in the same period 2014 due to a shift in product mix. Foreign currency exchange negatively impacted gross profit by approximately $(0.3) million and operating income was negatively impacted by approximately $(0.1) million.

 

Operating expenses, excluding intangible amortization charges, totaled $2.6 million versus $3.3 million in 2014 for the comparable period. Sales and marketing and research and development (R&D) expenses were down $0.6 million in 2015 as compared to the first half 2014 at $1.3 million, while general and administrative expenses decreased 6% over the same period. The operating profit was $0.1 million, as compared to a $0.1 million loss in the first half of 2014. EBITDA was $0.3 million as compared to an EBITDA of $0.1 million in 2014. The net loss was $0.2 million compared to the first half 2014 net loss of $0.5 million.

 

On the balance sheet, foreign currency differences arise on consolidation of subsidiaries whose functional currency is not the U.S. dollar. Our June 30 2015, accumulated other comprehensive income balance was $957,000, as compared to $(44,000) at June 30, 2014 and $812,000 at December 31, 2014.

 

 

 

 

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

In thousands except share and per share data

(unaudited)

 

Six Months EndedJune 30,

 

2015

 

2014

 

Revenue

$ 6,703

$ 8,319

Cost of sales

(3,941)

(5,116)

 

 

Gross profit

2,762

3,203

 

 

Operating expenses:

Selling expenses

(965)

(1,343)

General and administrative

(1,387)

(1,476)

Research and development

(288)

(465)

Amortization of intangibles

-

(61)

 

 

Total operating expenses

(2,640)

(3,345)

 

 

Gain (loss) from operations

122

(142 )

Other expense, net

(89)

(91)

Interest expense

(120)

(149)

Amortization of debt discount and financing costs

(86)

(102)

 

 

Loss from operations before income tax provision (benefit)

(173 )

(484 )

Income tax benefit

-

-

 

 

Net loss

(173 )

(484 )

Other comprehensive income:

Foreign currency translation

145

102

 

 

Total comprehensive loss

$ (28)

$ (382)

 

 

Basic and diluted net loss per share

$ (0.00 )

$ (0.01 )

 

 

Basic and diluted weighted average shares outstanding

83,665

83,665

 

 

 

FINANCIAL STATEMENTS

PROPHOTONIX LIMITED

 CONSOLIDATED BALANCE SHEETS

(unaudited)

 ($ in thousands except share and per share data)

 

For the Periods Ended June 30, 2015 and 2014

 

2015

 

2014

 

Assets

Current assets:

Cash and cash equivalents

$ 212

$ 253

Accounts receivable, less allowances of $22 in 2015 and $35 in 2014

2,237

2,648

Inventories

1,705

2,049

Prepaid expenses and other current assets

135

198

 

 

Total current assets

4,289

5,148

Net property, plant and equipment

145

230

Goodwill

392

482

Acquired intangible assets, net

-

41

Other long-term assets

140

277

 

 

Total assets

$ 4,966

$ 6,178

 

 

Liabilities and Stockholders' (Deficit)

Current liabilities:

Revolving credit facility

$ 1,088

$ 1,219

Current portion of long-term debt net of unamortized discount of $13 at June 30, 2015 and $18 at June 30, 2014

955

570

Capital lease obligations

-

5

Accounts payable

1,079

1,612

Accrued expenses

1,016

985

 

 

Total current liabilities

4,138

4,391

Long-term debt, unamortized discount of $3 at June 30, 2015 and $17 at June 30, 2014

1,063

2,310

Other long-term liabilities

178

178

 

 

Total liabilities

5,379

6,879

 

 

Stockholders' (deficit):

Common stock, par value $0.001; shares authorized 250,000,000 at June 30, 2015 and at June 30, 2014; 83,665,402 shares issued and outstanding at June 30, 2015 and at June 30, 2014

84

84

Paid-in capital

111,733

111,417

Accumulated deficit

(113,187 )

(112,158 )

Accumulated other comprehensive income

957

(44)

 

 

Total stockholders' (deficit)

(413)

(701)

 

 

Total liabilities and stockholders' deficit

$ 4,966

$ 6,178

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands

(unaudited)

 

Six Months EndedJune 30,

 

2015

 

2014

 

Operations

Net loss

$ (173)

$ (484)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock based compensation

150

114

Depreciation and amortization

54

146

Foreign exchange gain

(25)

88

Amortization of debt discount and financing costs

72

95

Loss on disposal of assets

-

4

Provision for inventories

34

48

Provision for bad debts

3

22

Other change in assets and liabilities:

Accounts receivable

145

(132)

Inventories

(207)

(111)

Prepaid expenses and other current assets

35

22

Accounts payable

(275)

82

Accrued expenses

118

(313)

Other assets and liabilities

4

-

 

 

Net cash used in operating activities

(65)

(419)

Financing

Net borrowing of revolving credit facility

48

101

Proceeds from long-term debt issuance

-

175

Principal repayment of long-term debt

(277)

(4)

 

 

Net cash provided by (used in) financing activities

(229)

272

Investing

Purchase of plant and equipment

(29)

(18)

 

 

Net cash used in investing activities

(29)

(18)

Effect of exchange rate on cash

204

16

 

 

Net change in cash and equivalents

(119)

(149)

Cash and equivalents, beginning of period

331

402

 

 

Cash and equivalents, end of period

$ 212

$ 253

 

 

Supplemental disclosure of cash flow information:

Cash paid for interest

$ 120

$ 149

 

 

 

 

 

 

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY / (DEFICIT)

 (in thousands)

 

 

 

Common Stock

 

Paid inCapital

 

AccumulatedDeficit

 

Accumulated Other Comprehensive Income

 

TotalStockholders'Equity (Deficit)

 

 

Shares

 

Par$0.001

 

 

 

Balance December 31, 2014

83,665

$ 84

$ 111,583

$ (113,014)

$ 812

$ (535)

 

Net loss

(173)

(173)

 

Translation adjustment.......

145

145

 

 

Share based compensation

-

-

150

-

-

150

 

 

 

 

 

 

 

 

Balance June 30, 2015 ...

83,665

$ 84

$ 111,733

$ (113,187)

$ 957

$ (413)

 

 

 

 

 

 

 

 

 

 

Values may not add due to rounding

 

 

Notes to unaudited Interim Results

 

Basis of Presentation

 

The Company financial reports are issued under the recognition and measurement principles of United States Generally Accepted Accounting Principles (GAAP). The Accompanying unaudited condensed consolidated financial reports reflect all adjustments of a normal recurring nature necessary for a fair statement of the (i) results of operations and comprehensive income (loss) for the six month periods ended June 30, 2015 and 2014; (ii) the financial position at June 30, 2015 and June 30, 2014; and (iii) the cash flows for the six month period ended June 30, 2015 and 2014. These interim results are not necessarily indicative of results for a full year or any other interim period.

 

 

Cautionary Statement 

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

 

 

 

Use of Non-GAAP Financial Measures

 

The Company provides non-GAAP financial measures, such as EBITDA, to complement its consolidated financial statements presented in accordance with GAAP. Non-GAAP financial measures do not have any standardized definition and, therefore, are unlikely to be comparable to similar measures presented by other reporting companies. These non-GAAP financial measures are intended to supplement the user's overall understanding of the Company's current financial and operating performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company's core operating results or business performance, which management uses to evaluate financial performance for purposes of planning for future periods. However, these non-GAAP financial measures are not intended to supersede or replace the Company's GAAP results.

 

The Company uses EBITDA (earnings before interest, taxes, depreciation, amortization, stock-based compensation and impairment charges) as a non-GAAP financial measure in this press release. A reconciliation of net loss to EBITDA for the six months ended June 30, 2015 and 2014 is as follows:

 

 

(in thousands)

Six Months Ended June 30,

2015

2014

Net Loss

(173)

(484)

Plus:

Interest and other expense, net

209

240

Amortization of debt discount and financing costs

86

102

Depreciation

54

85

Intangible asset amortization

-

61

Stock based compensation

150

114

EBITDA

326

118

 

 

 

 

 

 

 

 

 

 

# # # # #

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR BRGDCDSGBGUI
Date   Source Headline
16th Dec 20217:00 amRNSSale of ProPhotonix and cancelation of AIM Listing
17th Nov 20217:00 amRNSNotice of GM
11th Nov 202111:05 amRNSSecond Price Monitoring Extn
11th Nov 202111:00 amRNSPrice Monitoring Extension
11th Nov 20217:00 amRNSProPhotonix Announces Merger Agreement
2nd Nov 20217:00 amRNSProPhotonix Extends COBRA HyperSpec range
14th Sep 20217:00 amRNSProPhotonix announces the new UV COBRA Cure FX4
8th Sep 20217:00 amRNS2021 Half-year Report
9th Jun 20217:00 amRNSPosting of Annual Report and Accounts
2nd Jun 20217:00 amRNSNew Wavelengths added to UVC LED System
25th Mar 20217:00 amRNSResults for the year ended December 31, 2020
26th Jan 20217:00 amRNSNew Hyperspectral COBRA MultiSpec LED Line Light
16th Nov 20202:05 pmRNSSecond Price Monitoring Extn
16th Nov 20202:00 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSAdmission of Shares
10th Nov 20207:00 amRNSProPhotonix introduces 265nm UVC LED Lamp
9th Nov 20204:45 pmRNSResult of AGM and Director / PDMR Shareholdings
9th Oct 20207:00 amRNSPOSTING OF NOTICE OF ANNUAL GENERAL MEETING
8th Oct 20207:00 amRNSNew RGB-IR & RGB-White COBRA MultiSpec Line Lights
7th Oct 20203:07 pmRNSHolding(s) in Company
10th Sep 20207:00 amRNSINTERIM RESULTS FOR HALF YEAR ENDED JUNE 30, 2020
3rd Sep 20204:40 pmRNSSecond Price Monitoring Extn
3rd Sep 20204:35 pmRNSPrice Monitoring Extension
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
2nd Sep 20207:00 amRNSPROdigii Digital Lasers Range - 5 New Wavelengths
27th Aug 20207:00 amRNSRESULTS FOR THE YEAR ENDED DECEMBER 31, 2019
25th Aug 20201:47 pmRNSNOTICE OF EXTENSION OF RIGHTS PLAN
24th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSChange of Adviser and Director Disclosures
29th Jun 20207:00 amRNSCustom LED Backlight wins VSD Innovators Award
23rd Jun 20207:00 amRNSAccounts Reporting Extension & Trading Update
30th Apr 20207:00 amRNSDirectorate Change
9th Apr 20207:00 amRNSCOVID – 19 and Trading Update
19th Mar 20207:00 amRNS3 Year Framework Product Supply & IP Agreement
16th Mar 20207:00 amRNSProPhotonix - UV LED Water Disinfection
16th Jan 20207:00 amRNSTrading Update 2019
26th Nov 20197:00 amRNSHolding(s) in Company
10th Oct 20197:00 amRNS5-Year Master Purchase Agreement - Fortune 50 CGLM
12th Sep 20197:00 amRNSProPhotonix to Exhibit UV Lamps at Labelexpo 2019
6th Sep 20197:00 amRNSProPhotonix issues Half-year Report
3rd Sep 20197:00 amRNSNew High-Powered Red Laser Diode from Ushio
31st May 201911:59 amRNSProPhotonix Notification of Major Holdings
31st May 201911:58 amRNSProPhotonix Notification of Major Holdings
24th May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
23rd May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
17th May 20197:00 amRNSProPhotonix Announces Trading Update
16th May 20195:58 pmRNSPPIX Announces AGM Results and PDMR Shareholdings
16th May 20197:00 amRNSPPIX Offers New COBRA Cure Mini UV Curing System
9th Apr 20197:00 amRNSProPhotonix Honored by Vision Systems Design 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.